Safety of Opportunistic Salpingectomy During Elective Laparoscopic Cholecystectomy.

Safety of Opportunistic Salpingectomy During Elective Laparoscopic Cholecystectomy: A Randomized Controlled Trial

The knowledge, coupled with epidemiological studies demonstrating lower ovarian cancer rates in women with a history of tubal sterilization has led to recommendations for opportunistic salpingectomy at the time of benign gynecological surgery. However, this recommendation was not explored in the setting of non-gynecological surgeries, of most if the surgery performed not in pelvis.

This study aims to evaluate the safety of performing opportunistic salpingectomy at the time of elective laparoscopic cholecystectomy in women aged 45 years or older. Of note, the only available prospective study from Austria evaluated feasibility of combined operation. By assessing complication rates and other perioperative outcomes, the study seeks to determine if this combined approach is a safe for opportunistic ovarian cancer prevention. Ultimately, this research may inform surgical practice and potentially reduce the incidence of ovarian cancer in this population.

Study Overview

• Status: Active, not recruiting
• Conditions: Ovarian Cancer; Cholecystolithiasis
• Intervention / Treatment: Procedure: Opportunistic salpingectomy; Procedure: Cholecystectomy

• Study Type: Interventional
• Enrollment (Actual): 300
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Switzerland
  • Zurich, Switzerland, 8091
    • Division of Visceral Surgery and Transplantation , University Hospital Zurich

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Women aged 45 years or older.
• No known history of ovarian or fallopian tube cancer.
• Completed family planning.
• Scheduled to undergo elective laparoscopic cholecystectomy for benign gallbladder disease.
• Able to provide informed consent.
• Willing to comply with study procedures and follow-up assessments.

Exclusion Criteria:

• Previous abdominal Surgery or any inflammatory bowel disease.
• Current pregnancy or breastfeeding (verbally asked).
• Contraindications to laparoscopic surgery (e.g., severe cardiopulmonary disease, extensive prior abdominal surgery).
• Any medical condition that, in the opinion of the investigator, would preclude safe participation in the study or interfere with follow-up.
• Participation in another clinical trial that may confound the results of this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental group; Opportunistic salpingectomy during surgery.	Procedure: Opportunistic salpingectomy; Opportunistic salpingectomy at the time of elective laparoscopic cholecystectomy will be performed in study group, while the control group undergo cholecystectomy without salpingectomy.; Procedure: Cholecystectomy; Cholezystectomy as controll group
Active Comparator: Control group; Elective cholecystectomy	Procedure: Cholecystectomy; Cholezystectomy as controll group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Postoperative complications assesed with Comprehensive complication index.	This will be the primary outcome measure, encompassing any complications assessed with Comprehensive Complication Index. The range between 0 and 100. The higher score means more complications.	within 6 weeks after surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Operating time	Operating time measured in minutes from incision until skin stich	Operating time in minutes during surgical procedure
Length of hospital stay	Length of hospital stay calculated in days	Length of hospital stay: The number of days patients remain hospitalized after surgery untill discharge assedd at discharge (assessed at around 5 days).

Collaborators and Investigators

• Sponsor: University of Zurich
• Investigators: Principal Investigator: Dilmurodjon MDE Eshmuminov, MD, Univercity hospital zurich

Study record dates

Study Major Dates

• Study Start (Actual): April 15, 2026
• Primary Completion (Estimated): May 31, 2028
• Study Completion (Estimated): May 31, 2029

Study Registration Dates

• First Submitted: April 17, 2026
• First Submitted That Met QC Criteria: June 8, 2026
• First Posted (Actual): June 11, 2026

Study Record Updates

• Last Update Posted (Actual): June 11, 2026
• Last Update Submitted That Met QC Criteria: June 8, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Endocrine System Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Digestive System Diseases; Genital Diseases, Female; Endocrine Gland Neoplasms; Biliary Tract Diseases; Ovarian Diseases; Adnexal Diseases; Genital Neoplasms, Female; Gonadal Disorders; Gallbladder Diseases; Cholelithiasis; Ovarian Neoplasms; Cholecystolithiasis; Surgical Procedures, Operative; Digestive System Surgical Procedures; Biliary Tract Surgical Procedures; Cholecystectomy
• Other Study ID Numbers: 2026-00157

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No